CA
ABOS icon

Clearstead Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Clearstead Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60
Closed -$142 – 3660
2026
Q1 		$142 Hold
60
– – ﹤0.01% 2187
2025
Q4 		$127 Buy
+60
New +$119 ﹤0.01% 2479
2025
Q3 		– Sell
-63
Closed -$74 – 3087
2025
Q2 		$74 Buy
+63
New +$68 ﹤0.01% 2644

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Clearstead Advisors's ABOS Position: Q2 2026 in Review

Clearstead Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 60 shares — an estimated $142 sold.

Clearstead Advisors first reported a position in ABOS in Q2 2025 and held it in 3 quarters. The position peaked at $142 in Q1 2026. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Clearstead Advisors reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Clearstead Advisors sold 60 Acumen Pharmaceuticals shares in Q2 2026, an estimated $142.
  • Clearstead Advisors first reported a position in Acumen Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Clearstead Advisors's Acumen Pharmaceuticals position peaked at $142 in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.